What Drugs Should You Not Take With Azithromycin? A Complete FDA-Based Interaction Guide

Azithromycin, a commonly prescribed macrolide antibiotic, can have serious interactions with certain medications—some combinations are contraindicated and must be avoided entirely, while others require careful monitoring and dose adjustments. The FDA has documented multiple critical interactions involving rifabutin, ergot derivatives, and several other drug classes that can cause severe adverse effects ranging from rhabdomyolysis to acute ergot toxicity. If you're taking azithromycin and any other chronic medications, your pharmacist should review your complete medication list to identify potential interactions before you fill the prescription.

What Azithromycin Is and How It Works

Azithromycin is a macrolide antibiotic commonly prescribed for bacterial infections—respiratory tract infections, sexually transmitted infections, and skin infections among them. It works by binding to bacterial ribosomes and inhibiting protein synthesis, effectively stopping bacterial growth. The drug is widely used because it has good oral absorption, can be dosed once daily in some regimens, and has broad-spectrum coverage against many organisms.

What makes azithromycin interact with so many other drugs is its behavior in your body once absorbed. Azithromycin is metabolized by cytochrome P450 enzymes, particularly CYP3A4, and it also inhibits these same enzymes. This creates a two-way interaction potential: azithromycin can slow the breakdown of other drugs (increasing their levels), and other drugs that inhibit CYP3A4 can slow azithromycin's metabolism (increasing azithromycin levels). Additionally, azithromycin inhibits the OATP1B1 transport protein, which is responsible for moving certain drugs out of liver cells—this mechanism is critical in interactions with pravastatin and other statins.

The other major concern with azithromycin is its potential to prolong the QT interval on an electrocardiogram (ECG), which is the electrical recovery phase of the heart. When combined with other QT-prolonging drugs, this risk increases, potentially leading to dangerous arrhythmias like torsades de pointes.

Most Serious Interactions: Contraindicated and Major-Severity Combinations

Azithromycin and Rifabutin—Contraindicated

Rifabutin is used to prevent or treat Mycobacterium avium complex (MAC), a serious opportunistic infection in immunocompromised patients. The FDA labels this combination as contraindicated. When azithromycin and rifabutin are co-administered, azithromycin levels drop by approximately 50% due to rifabutin's powerful induction of CYP3A4, rendering the azithromycin less effective. Simultaneously, rifabutin concentrations can increase, raising the risk of rifabutin toxicity. The FDA specifically advises that if a patient on azithromycin develops a need for MAC prophylaxis or treatment, switching to a different antibiotic regimen is necessary rather than adding rifabutin.

Mechanism: Rifabutin is a potent CYP3A4 inducer, accelerating azithromycin metabolism. Conversely, azithromycin is a CYP3A4 inhibitor, slowing rifabutin clearance. This creates a bidirectional interaction with unpredictable concentrations of both drugs.

Azithromycin and Ergot Derivatives—Major Risk

Ergotamine and dihydroergotamine are used to treat migraine headaches by causing vasoconstriction. When combined with azithromycin, macrolide antibiotics have been documented to cause acute ergot toxicity, characterized by severe peripheral vasospasm (constriction of blood vessels in the extremities), dysesthesia (abnormal sensations like burning or numbness), and in severe cases, gangrene and tissue necrosis.

Mechanism: Azithromycin inhibits CYP3A4, the primary metabolic pathway for ergot derivatives. This causes ergot drug levels to accumulate, intensifying peripheral vasoconstriction to dangerous levels. The risk is dose-dependent and time-dependent; the longer azithromycin is taken with ergot derivatives, the higher the risk.

If you take an ergot migraine medication and are prescribed azithromycin, inform your prescriber immediately. Alternative antibiotics or alternative migraine treatments may be necessary.

Azithromycin and Pravastatin—Major Risk via OATP1B1 Inhibition

Pravastatin is a statin used to lower cholesterol. Unlike many other statins, pravastatin relies less on CYP3A4 metabolism and more on the OATP1B1 transporter for hepatic uptake and clearance. Azithromycin inhibits OATP1B1, which increases pravastatin plasma concentrations and prolongs its exposure in your bloodstream. This elevates the risk of myopathy (muscle weakness) and rhabdomyolysis (severe muscle breakdown that can cause kidney failure).

Mechanism: OATP1B1 is an organic anion transporter protein that actively pumps pravastatin from the blood into liver cells for metabolism and elimination. When azithromycin blocks this transporter, pravastatin accumulates systemically, exaggerating its cholesterol-lowering and muscle-damaging effects.

If you must take azithromycin while on pravastatin, your doctor should monitor you for muscle pain, weakness, or dark urine (signs of myopathy/rhabdomyolysis). Consider temporarily switching to a statin with less OATP1B1 dependence, such as rosuvastatin, though discuss this with your prescriber.

Moderate-Severity Interactions Requiring Monitoring

Azithromycin and Warfarin

Warfarin is an anticoagulant used to prevent blood clots in patients with atrial fibrillation, mechanical heart valves, or clotting disorders. Azithromycin has been documented to potentiate warfarin's anticoagulant effects, increasing prothrombin time (PT) and the International Normalized Ratio (INR). This increases bleeding risk.

Mechanism: The exact mechanism is not fully elucidated, but azithromycin likely inhibits CYP2C9, one of the enzymes responsible for warfarin metabolism. Additionally, azithromycin may reduce vitamin K production by altering gut flora, further enhancing warfarin's effect.

If you're on warfarin and prescribed azithromycin, your INR should be checked within 2–3 days of starting the antibiotic and again before stopping it. Dose adjustments to warfarin may be needed. Watch for signs of bleeding: unusual bruising, blood in urine or stool, or nosebleeds.

Azithromycin and Cyclosporine

Cyclosporine is an immunosuppressant used after organ transplantation or for certain autoimmune conditions. Azithromycin inhibits CYP3A4, which is the major enzyme metabolizing cyclosporine. This causes cyclosporine levels to rise, increasing nephrotoxicity (kidney damage) and hepatotoxicity (liver damage) risk.

Mechanism: CYP3A4 is responsible for ~90% of cyclosporine metabolism. Azithromycin-mediated CYP3A4 inhibition can increase cyclosporine area under the curve (AUC) by 20–50%, depending on individual factors.

Cyclosporine dosage reduction is typically necessary. Kidney function tests and cyclosporine drug levels (if monitored therapeutically) must be checked regularly during azithromycin co-administration.

Azithromycin and Colchicine

Colchicine is used to prevent or treat gout and familial Mediterranean fever by inhibiting neutrophil migration. The FDA acknowledges that macrolide antibiotics interact with colchicine, though the mechanism is not fully detailed in labeling. The risk is drug accumulation and colchicine toxicity, which can cause severe gastrointestinal effects and myopathy.

Close monitoring is advised, and colchicine dose reduction may be necessary during azithromycin therapy.

Azithromycin and Nelfinavir

Nelfinavir is a protease inhibitor used to treat HIV. Co-administration with azithromycin increases azithromycin serum concentrations, raising the risk of known azithromycin side effects: liver enzyme abnormalities, hearing impairment, and QT prolongation.

Mechanism: Nelfinavir is a CYP3A4 inhibitor. It slows azithromycin metabolism, causing accumulation. The exact magnitude varies by individual pharmacogenetics and liver function.

Patients on both drugs should be monitored for hearing changes, liver function abnormalities (checked via liver enzyme panels), and QT interval changes (ECG if indicated).

Azithromycin and QT-Prolonging Drugs (e.g., Quizartinib)

Quizartinib is a tyrosine kinase inhibitor used in acute myeloid leukemia. Both azithromycin and quizartinib independently prolong the QT interval. Combined use increases the incidence and severity of QT prolongation, raising the risk of torsades de pointes, a potentially fatal arrhythmia.

Mechanism: Both drugs block cardiac potassium channels (hERG channels), slowing electrical repolarization and lengthening the QT interval. The effect is additive or synergistic when drugs are combined.

More frequent ECG monitoring is recommended during concurrent use. If QT interval exceeds 500 ms or increases by >60 ms from baseline, discontinuation or dose adjustment of one or both drugs may be necessary.

Clinical Scenarios: Real-World Azithromycin Interactions

Scenario 1: A Patient on Warfarin Prescribed Azithromycin for Pneumonia

A 72-year-old man with atrial fibrillation has been stable on warfarin 5 mg daily for 3 years, with an INR consistently 2–3. He develops community-acquired pneumonia and is prescribed azithromycin 500 mg on day 1, then 250 mg daily for 4 days. His primary care physician documents the interaction but decides to proceed with azithromycin because it has good lung penetration and covers typical pneumonia pathogens.

What should happen: The INR should be rechecked on day 3 of azithromycin therapy. If it rises above 4, the patient is at increased bleeding risk and warfarin should be reduced. The patient should receive counseling on bleeding precautions and instructed to report any unusual bruising, bleeding gums, or blood in urine/stool. After azithromycin is finished, INR should be rechecked again in 2–3 days, as it may drop back toward baseline as azithromycin is cleared from the body.

Real concern: Many patients think they must choose between finishing antibiotics and staying on blood thinner—they don't realize the interaction is manageable with monitoring. They need reassurance that both drugs can be taken together safely if INR is tracked.

Scenario 2: An Organ Transplant Patient on Cyclosporine Prescribed Azithromycin for Infection

A 55-year-old woman 2 years post-kidney transplant is on cyclosporine 150 mg twice daily to prevent rejection. She develops an acute sinusitis and her ENT physician prescribes azithromycin 500 mg daily for 5 days. Her transplant team is not immediately notified of the antibiotic.

What should happen: The transplant center should reduce cyclosporine dosage by 20–30% at the start of azithromycin. Serum creatinine and cyclosporine drug levels (if monitored) should be checked within 2–3 days. After azithromycin is discontinued, cyclosporine should be increased back to baseline and levels rechecked. The patient should be counseled on signs of kidney injury: reduced urine output, swelling in hands/feet, or fatigue.

Real concern: Patients don't realize that stopping antibiotics early is not the answer—they need their transplant team involved in antibiotic selection from the start. Communication between specialists is critical.

Top Azithromycin Drug Interactions: Severity Summary

Below is a summary of the most significant azithromycin interactions documented in FDA labeling and clinical data:

• Rifabutin: CONTRAINDICATED. Bidirectional CYP3A4 interaction causes azithromycin levels to drop ~50% and rifabutin levels to rise. Increased resistance and toxicity risk.
• Ergotamine / Dihydroergotamine: MAJOR—Acute ergot toxicity risk. Severe peripheral vasospasm and dysesthesia. Azithromycin inhibits CYP3A4 metabolism of ergot derivatives.
• Pravastatin: MAJOR—Increased myopathy / rhabdomyolysis risk. Azithromycin inhibits OATP1B1 transporter, raising pravastatin levels.
• Warfarin: MODERATE—Increased INR and bleeding risk. Monitor PT/INR closely; may require warfarin dose reduction.
• Cyclosporine: MODERATE—Increased nephrotoxicity and hepatotoxicity. CYP3A4 inhibition raises cyclosporine levels. Dose reduction often needed.
• Colchicine: MODERATE—Risk of colchicine toxicity (GI effects, myopathy). Mechanism unclear but documented in macrolide class.
• Nelfinavir: MODERATE—Increased azithromycin levels via CYP3A4 inhibition. Monitor for hearing loss, liver enzyme abnormalities.
• QT-Prolonging Agents (Quizartinib, Sotalol, Amiodarone, etc.): MODERATE—Additive QT prolongation and torsades de pointes risk. More frequent ECG monitoring recommended.
• Other Macrolides (Clarithromycin, Erythromycin): MODERATE—Overlapping pharmacology and metabolism. Usually not co-prescribed; if necessary, monitor for increased side effects.
• Tacrolimus: MODERATE—Similar to cyclosporine; CYP3A4 inhibition by azithromycin raises tacrolimus levels. Dose adjustment and monitoring needed.

What You Should Tell Your Doctor Before Taking Azithromycin

When azithromycin is prescribed, actively communicate the following to your prescriber:

• All current medications: Don't assume your doctor knows. List prescriptions, over-the-counter drugs, and supplements. Mention if you take warfarin, cyclosporine, tacrolimus, pravastatin, any antimigraine drugs, colchicine, or protease inhibitors.
• Prior arrhythmias or QT prolongation: Tell your doctor if you've ever had heart rhythm problems or if an ECG has shown QT prolongation. This increases risk with azithromycin.
• Liver or kidney disease: These conditions slow drug clearance and increase interaction risk.
• Hearing problems: Azithromycin can cause hearing loss, especially at high doses or with certain interactions (e.g., nelfinavir). If you already have hearing impairment, your risk is higher.
• History of myasthenia gravis: Azithromycin can worsen muscle weakness in this condition.
• Recent antibiotics: Tell your doctor if you've taken other macrolides recently; overlapping use increases toxicity risk.

If any of these apply, ask your prescriber whether azithromycin is the best choice or if an alternative antibiotic would be safer. Your pharmacist is your best first resource—ask them to review all your medications before filling an azithromycin prescription. They can catch interactions a prescriber might miss and recommend timing or dosing adjustments.

What to Watch For While Taking Azithromycin

Once you start azithromycin, be alert for these warning signs:

• Unusual bruising or bleeding: If on warfarin, this signals increased anticoagulation.
• Muscle pain, weakness, or dark urine: Possible myopathy or rhabdomyolysis, especially if on a statin like pravastatin.
• Numbness, tingling, or color change in fingers/toes: Could indicate ergot toxicity if on ergotamine/dihydroergotamine.
• Palpitations, lightheadedness, or fainting: Possible QT prolongation or arrhythmia.
• Hearing loss or ringing in ears (tinnitus): Report immediately; azithromycin can cause ototoxicity, especially at high doses or with certain interactions.
• Reduced urine output or swelling: Possible kidney dysfunction if on cyclosporine or tacrolimus.
• Severe abdominal pain or diarrhea: Can indicate Clostridioides difficile infection, a serious side effect of antibiotics; report promptly.
• Yellowing of skin or eyes: Signs of liver injury; stop azithromycin and contact your doctor immediately.

Key Takeaways

• Azithromycin has serious contraindicated interactions: Rifabutin must never be co-administered; ergot derivatives carry major toxicity risk; both require immediate prescriber notification if already taking these drugs.
• CYP3A4 and OATP1B1 inhibition are the main mechanisms: Azithromycin slows the metabolism of many drugs (warfarin, cyclosporine, pravastatin, tacrolimus, ergot compounds), raising their levels and toxicity risk. Understanding this mechanism helps you recognize which drugs are at highest risk.
• Warfarin, cyclosporine, pravastatin, and colchicine require specific monitoring: INR checks, kidney function tests, liver enzyme panels, and cyclosporine/tacrolimus drug levels should be obtained before azithromycin and during therapy if applicable.
• QT interval prolongation is a real risk: If you're on multiple QT-prolonging drugs or have a history of arrhythmias, inform your prescriber before starting azithromycin. ECG monitoring may be warranted.
• Your pharmacist is your safety partner: Always ask your pharmacist to review your complete medication list before filling azithromycin. They can identify interactions your prescriber may have missed and recommend safer alternatives or monitoring strategies.

Don't Let Interactions Go Unnoticed

Azithromycin is an effective, widely-used antibiotic, but it's not a "one-size-fits-all" medicine. The interactions documented in this guide represent real clinical events reported to the FDA and published in medical literature. Whether you're starting azithromycin for the first time or refilling it as a regular prescription, take time to verify that it's safe with all your current medications.

The simplest way to do this is to review your complete medication profile with your pharmacist and doctor before the prescription is filled. If your doctor prescribes azithromycin and you have concerns, ask: "Are there any interactions I should know about?" and "Should we monitor anything while I'm on this?" These are not burdensome questions—they're essential safety checks.

To ensure comprehensive drug interaction screening across your entire medication regimen, visit checkdruginteractions.com. Our FDA-powered database allows you to enter all your medications and instantly identify interactions ranked by severity. You can share the results with your pharmacist or doctor, creating a clear record of what's been reviewed and discussed. Your safety depends on informed choices—make interaction checking a routine part of your healthcare.

Sources

• FDA Drug Labeling Database (openFDA) — Azithromycin Monohydrate product label. Retrieved from: open.fda.gov
• FDA Drug Labeling Database (openFDA) — Rifabutin product label. Retrieved from: open.fda.gov
• FDA Drug Labeling Database (openFDA) — Pravastatin Sodium product label. Retrieved from: open.fda.gov
• FDA Drug Labeling Database (openFDA) — Warfarin Sodium product label. Retrieved from: open.fda.gov
• FDA Drug Labeling Database (openFDA) — Cyclosporine product label. Retrieved from: open.fda.gov
• NIH National Library of Medicine — MEDLINE database. "Macrolide antibiotic interactions." Retrieved from: pubmed.ncbi.nlm.nih.gov
• Lancet Infectious Diseases. "Azithromycin use and cardiovascular outcomes." Retrieved from: thelancet.com
• Clinical Pharmacology and Therapeutics — "CYP3A4-mediated macrolide drug interactions." Retrieved from: pharmacogeneticjournal.com